獸醫 動物科技 試劑 耗材
製藥等級耗材(Pharmaceutical grade)
產程(Bulk)需求
Protein
Hot!!! Top sales 10
Antibiotics
Stem Cell
研究用抗癌藥物
Screening Libraries 篩選庫
過濾設備
Inhibitors 抑制劑
氧化鋁材料開發
實驗耗材
基礎分生
初級抗體
二級抗體
Normal Serum
ELISA KIT
IHC KIT
Proteomics
生化分析
化學藥品
BUFFER
Smart Solution
實驗儀器
電泳配件
水質檢測
細胞生物
In-Vitro Diagnostic   體外診斷試劑組
中草藥標準品
委託服務
GMP cytokine
GMP Medium
GMP antibody
GMP Antigens
 

首頁 > 最新消息

Tropifexor ( LJN452 ) ,a novel and highly potent agonist of FXR

Tropifexor ( LJN452 ) is a novel and highly potent agonist of FXR with an EC50 of 0.2 nM in HTRF assay. It shows no significant off-target activity against a broad panel of enzyme, ion channel, nuclear receptor, and GPCR (>10000-fold selectivity for FXR). Robust induction of both BSEP and SHP genes is observed in primary cells by Tropifexor in a concentration-dependent manner. BSEP induction above vehicle (DMSO) control is observed at concentrations as low as 1 nM, while strong induction of SHP (15-fold above vehicle) is observed at 10 nM and modest induction of SHP at 1 nM (3-fold).Tropifexor demonstrates highly potent induction of SHP and FGF15 in the ileum as doses as low as 0.1 mg/kg. In the liver, robust induction of SHP is observed at 0.01 mg/kg of Tropifexor with maximal levels of gene induction achieved at 0.3 mg/kg. Expression of CYP8B1 mRNA following 14 day treatment with Tropifexor is already apparent at the lowest dose (0.003 mg/kg), and CYP8B1 gene expression is fully repressed at doses above 0.03 mg/kg. Treatment of rats with Tropifexor exhibits a clear dose-dependent increase in plasma FGF15 protein, with maximal levels of FGF15 detected at 7 h postdose. Treatment with Tropifexor for 14 days produces a robust dose-dependent reduction in serum triglycerides and reaches a maximal response with a 0.3 mg/kg dose, resulting in a decrease of triglyceride levels to approximately 79% below the vehicle control group.

 

 

 Tropifexor (LJN452) Chemical Structure                                CAS.No.: 1383816-29-2

 

 

 
 


     橘創整合行銷有限公司 』 建置